この専門家をプロジェクトに採用したいですか？ 見積もりを依頼 無料で。
プロフィール詳細
Andrew M.に依頼
United Kingdom
Health Economist and Decision Analysis modeller | Modelling Expert in Simul8 and Excel
プロフィール概要
専門分野
サービス
Writing
Technical Writing
Research
Meta-Research,
Fact Checking,
Systematic Literature Review
Consulting
Scientific and Technical Consulting
Data & AI
Statistical Analysis
職務経験
The University of Sheffield
1月 2019 - 現在 
学歴
MSc in Health Economics and Decision Modelling
The University of Sheffield
9月 2017 - 9月 2018
認定資格
- 認定資格の詳細は未入力です。
出版物
JOURNAL ARTICLE
Andrew Metry, Becky Pennington, Abualbishr Alshreef, Laura Flight, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana C. Vasconcelos, Caroline Murphy, et al.(2021). Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study . PharmacoEconomics. Springer Science and Business Media {LLC}
Andrew Metry, Becky Pennington, Abualbishr Alshreef, Laura Flight, Edith Poku, Philip Hykin, Sobha Sivaprasad, A. Toby Prevost, Joana C. Vasconcelos, Caroline Murphy, et al.(2021). Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study . PharmacoEconomics. Springer Science and Business Media {LLC}
Andrew Metry, Ana Duarte, Simon Walker, Ruth Wong, Jasmina Panovska-Griffiths, Mark Sculpher(2021). Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK Studies . PharmacoEconomics. Springer Science and Business Media {LLC}
Andrew Metry, Ana Duarte, Simon Walker, Ruth Wong, Jasmina Panovska-Griffiths, Mark Sculpher(2021). Jointly modelling economics and epidemiology to support public policy decisions for the COVID-19 response : a review of UK studies . Pharmacoeconomics Italian Research Articles. 39. (8). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 879--887. Springer Nature
Andrew Metry, Philip Hykin, A Toby Prevost, Sobha Sivaprasad, Joana C Vasconcelos, Caroline Murphy, Joanna Kelly, Jayashree Ramu, Abualbishr Alshreef, Laura Flight, et al.(2021). Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT . Health Technology Assessment. 25. (83). NIHR Journals Library
Andrew Metry, Matt Stevenson, Michael Messenger (2021). Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis . Health Technology Assessment.
Andrew Metry, Matt, Michael Messenger(2021). Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis . Health Technology Assessment. 25. (39). National Institute for Health Research
Andrew Metry, Becky Pennington, Abualbishr Alshreef, Laura Flight, Edith Poku, Philip Hykin, Sobha Sivaprasad, A Toby Prevost, Joana C Vasconcelos, Caroline Murphy, et al.(2021). Cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study . Pharmacoeconomics Italian Research Articles. Springer
Andrew Metry, Matt Stevenson, Michael Messenger(2021). Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis . Health Technology Assessment. 25. (21). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1--68. National Institute for Health Research
Andrew Metry, Matt, Michael Messenger(2021). Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E : rapid cost-effectiveness analysis . Health Technology Assessment. 25. (21). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1--68. National Institute for Health Research
Andrew Metry, Becky Pennington, Abualbishr Alshreef, Laura Flight, Edith Poku, Philip Hykin, Sobha Sivaprasad, A Toby Prevost, Joana C Vasconcelos, Caroline Murphy, et al. Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study . Pharmacoeconomics Italian Research Articles. Springer Science and Business Media LLC
CONFERENCE PAPER
Andrew Metry, W Sullivan, Benjamin Kearns, Ash Bullement(2019). PDB32 WOULD A COHORT-LEVEL APPROACH TO COST-EFFECTIVENESS MODELLING HAVE LED TO A DIFFERENT DECISION IN AN IMPORTANT NICE APPRAISAL FOR OBESITY PATIENTS? . Value in Health. 22. Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString S577--S578. Elsevier BV
Andrew Metry, G H Elsisi, Z A Elshafei(2017). COST-MINIMIZATION ANALYSES OF BIOLOGICAL THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS FROM THE EGYPTIAN HEALTHCARE SYSTEM PERSPECTIVE. Value in Health. 20. (9). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString A535--A536.
Andrew Metry, E A Elshikh, I Anan, A A Ebaid, Al Gamal DA, M M Hamed, E A Mouein(2015). A Cross-Sectional Epidemiological Cancer Registry In Egypt . Value in Health. 18. (7). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString A437--A437. Elsevier BV
Andrew Metry, H Elmansy, R Eldessouki, G Elsisi(2015). Cost-Effectiveness of Zoledronic Acid Versus Alendronic Acid In The Treatment of Osteoporosis In Postmenopausal Egyptian Patients: Decision Analysis . Value in Health. 18. (7). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString A646--A646. Elsevier BV
Andrew Metry, Abo A M Taleb, A S Saad, K A Kamal(2015). DEVELOPING HOSPITAL BASED HTA FOR EGYPTIAN CANCER PATIENTS. Value in Health. 18. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString A102--A102.
評価とコメント
受注プロジェクト総数:
コメント: